CME Group (CME) director granted 645 fully vested shares at $225

Rhea-AI Filing Summary

Seifu Rahael reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Seifu Rahael received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were issued at a value of $225.00 per share as part of the company’s annual equity compensation program for non-employee directors.

The footnote explains these are fully vested shares under the CME Group Director Stock Plan and are not subject to any vesting conditions. Following this award, Rahael directly holds 4,739 Class A shares, reflecting routine, compensation-related equity rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Seifu Rahael

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K

Holdings After Transaction: Common Stock Class A — 4,739 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 645 shares Grant price per share: $225.00 per share Shares held after transaction: 4,739 shares

3 metrics

Shares granted 645 shares Class A common stock grant on June 25, 2026

Grant price per share $225.00 per share Value reported for equity award

Shares held after transaction 4,739 shares Director’s direct Class A holdings post-grant

Key Terms

annual equity compensation program, CME Group Director Stock Plan, fully vested shares, non-employee directors

4 terms

annual equity compensation program financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors"

CME Group Director Stock Plan financial

"for non-employee directors under the CME Group Director Stock Plan"

fully vested shares financial

"Represents a grant of fully vested shares of Class A Common Stock"

non-employee directors financial

"annual equity compensation program for non-employee directors"

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:28 PM Accepted by SEC EDGAR 06/29/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seifu Rahael

(Last) (First) (Middle)

20 S. WACKER DR.

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	4,739	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Rahael Seifu	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CME (CME) director Seifu Rahael report in this Form 4?

Seifu Rahael reported receiving 645 shares of CME Group Class A common stock as an equity award. The grant reflects routine board compensation and was made under the company’s director stock plan for non-employee directors.

Was the CME (CME) Form 4 transaction a market purchase or a grant?

The transaction was a grant, not a market purchase. Rahael received 645 fully vested Class A shares as part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.

What price per share was used for the CME (CME) director stock grant?

The Form 4 reports a value of $225.00 per share for the 645 Class A shares granted. This figure typically reflects the fair market value used to measure the equity compensation award for reporting and compensation purposes.

How many CME (CME) shares does director Seifu Rahael hold after this grant?

After receiving the 645-share grant, Rahael directly holds 4,739 shares of CME Group Class A common stock. This total reflects his direct ownership position immediately following the reported equity compensation transaction.

Are the CME (CME) shares granted to Seifu Rahael subject to vesting?

No. The footnote states the 645 Class A shares are fully vested and not subject to any vesting conditions. They were issued under CME Group’s annual equity compensation program for non-employee directors.